Valuation: Jade Biosciences, Inc.

Market Cap 133.26Cr 116.74Cr 107.62Cr 100Cr 188.87Cr 13TCr 192.33Cr 1.29TCr 502.48Cr 6.24TCr 500.4Cr 489.45Cr 22TCr P/E 2026 *
-8.63x
P/E 2027 * -8.71x
Enterprise Value 107.91Cr 95Cr 87Cr 81Cr 152.94Cr 10TCr 155.74Cr 1.05TCr 406.89Cr 5.05TCr 405.2Cr 396.33Cr 18TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Jade Biosciences, Inc.

1 day+0.36%
1 week+1.40%
Current month+1.40%
1 month+33.00%
3 months+37.71%
6 months+70.88%
Current year+46.01%
1 week 20.2
Extreme 20.2
23.36
1 month 14.28
Extreme 14.28
23.49
Current year 12.45
Extreme 12.45
28
1 year 6.67
Extreme 6.67
28
3 years 6.56
Extreme 6.565
28
5 years 6.56
Extreme 6.565
28
10 years 6.56
Extreme 6.565
28
Manager TitleAgeSince
Chief Executive Officer 50 28/04/2025
Director of Finance/CFO 38 14/07/2025
Chief Tech/Sci/R&D Officer 53 22/04/2026
Director TitleAgeSince
Director/Board Member 50 28/04/2025
Director/Board Member 42 28/04/2025
Chairman 57 28/04/2025
Date Insider Type Main position Quantity % Market Cap.
25/06Free

Director

47,675 0.0966%
09/06
Fairmount Funds Management LLC
FreeCompany 34,843 0.0706%
09/06Free

Director

34,843 0.0706%
Change 5-day change 1-year change 3-year change Capi.($)
+0.36%+1.40%+115.60% - 133.26Cr
-0.24%+4.98%+2.69%+9.14% 4.97TCr
-0.36%+1.33%+417.51%+619.10% 4.05TCr
-2.29%+5.93%+25.27%+59.26% 3.43TCr
-2.13%+5.47%+25.45%-6.01% 3.48TCr
-0.79%+2.02%+3.83%+36.42% 2.7TCr
+3.82%+3.92% - - 1.66TCr
-2.62%+0.45%+66.82%+125.87% 1.56TCr
-2.17%+6.52%+102.15%+102.15% 1.43TCr
-2.70%-2.19%+11.25%+18.19% 1.38TCr
Average -0.91%+3.69%+85.62%+120.52% 2.48TCr
Weighted average by Cap. -0.99%+4.35%+93.84%+139.18%

Financials

2026 *2027 *
Net sales - -
Net income -17Cr -15Cr -14Cr -13Cr -25Cr -1.65TCr -25Cr -167.73Cr -65Cr -811.35Cr -65Cr -64Cr -2.82TCr -19Cr -17Cr -15Cr -14Cr -27Cr -1.83TCr -28Cr -185.13Cr -72Cr -895.54Cr -72Cr -70Cr -3.11TCr
Net Debt -25Cr -22Cr -20Cr -19Cr -36Cr -2.42TCr -37Cr -245.51Cr -96Cr -1.19TCr -95Cr -93Cr -4.12TCr -30Cr -26Cr -24Cr -22Cr -43Cr -2.87TCr -43Cr -290.78Cr -113.22Cr -1.41TCr -112.75Cr -110.28Cr -4.88TCr
Logo Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company, which is focused on developing therapies for autoimmune diseases. The Company’s lead asset, JADE-001, is an investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of Immunoglobulin A (IgA) nephropathy (IgAN), an autoimmune condition in which the kidney is damaged by pathogenic IgA containing immune complexes, leading to proteinuria and kidney function decline, and potentially progressing to end-stage kidney disease requiring dialysis or transplantation. Designed to block the APRIL protein, JADE-001 targets an underlying cause of IgAN, offering the potential to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function over the long term. The Company’s pipeline also includes two undisclosed antibody discovery programs: JADE-002 and JADE-003, which are in preclinical development.
Employees
55
Date Price Change Volume
08/26/08 $22.53 +0.36% 8,57,284
07/26/07 $22.45 +5.40% 10,42,841
06/26/06 $21.30 -0.98% 10,56,288
02/26/02 $21.51 -1.38% 12,04,531
01/26/01 $21.81 -1.85% 8,61,567
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
22.45USD
Average target price
48.50USD
Spread / Average Target
+116.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. JBIO Stock